SecurityXENT / Intersect ENT, Inc. (46071F103)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding30,454,533 shares (as of 2018-06-30)
Total Insiders28
Total Directors9
Total Officers9

Stock Insider Trading (from SEC Form 4)

Intersect ENT, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

XENT / Intersect ENT, Inc. insiders include McKhann Chas FEDERMAN IRWIN, Lucchese Cynthia L, U S Venture Partners IX L P, VERNON W ANTHONY, Mead Dana G Jr., Tansey Casey M, YOUNG PHILIP M, Presidio Management Group IX, L.L.C., MOLL FREDERIC H, Wolbeck Amy, KPCB XI Associates, LLC, HILLEMAN JERYL L, Matteucci Paul A, Earnhardt Lisa D, Stambaugh James, ROOT JONATHAN D, KLEINER PERKINS CAUFIELD & BYERS XI-A LP, LIDDLE DAVID E, Lehman David Aaron, Parker Drake R., Kline Teresa L., KLEINER PERKINS CAUFIELD & BYERS XI B LP, de Clercq Casper L., and GALLAHUE KIERAN, CARSCADDEN GWEN R., Kaufman Richard E, KRAUSZ STEVEN M, .

Insider Roster

Insider Dir Off 10% Shares Owned
Earnhardt Lisa D President and CEO, Director
X X 465,865
Mead Dana G Jr. Director
X 13,567
Kaufman Richard E Sr VP& Chief Operating Officer
X 87,512
HILLEMAN JERYL L Chief Financial Officer
X 23,432
GALLAHUE KIERAN Director
X 12,060
Lucchese Cynthia L Director
X 9,060
MOLL FREDERIC H Director
X 241,138
Kline Teresa L. Director
X 1,514
VERNON W ANTHONY Director
X 4,060
Lehman David Aaron General Counsel
X 15,213
CARSCADDEN GWEN R. Chief People Officer
X 9,156
Parker Drake R. Chief Business Officer
X 3,000
Tansey Casey M Director
X 2,546
Wolbeck Amy V.P. Regulatory Affairs & Qlty
X
Stambaugh James VP Clinical Affairs
X
McKhann Chas Chief Commercial Officer
X
de Clercq Casper L. Director
X
KLEINER PERKINS CAUFIELD & BYERS XI B LP 10% Owner
KPCB XI Associates, LLC 10% Owner
KLEINER PERKINS CAUFIELD & BYERS XI-A LP 10% Owner
X
LIDDLE DAVID E 10% Owner
YOUNG PHILIP M 10% Owner
ROOT JONATHAN D 10% Owner
Matteucci Paul A 10% Owner
KRAUSZ STEVEN M 10% Owner
Presidio Management Group IX, L.L.C. 10% Owner
U S Venture Partners IX L P 10% Owner
FEDERMAN IRWIN 10% Owner
X
KPCB XI Associates, LLC 10% Owner
KLEINER PERKINS CAUFIELD & BYERS XI B LP 10% Owner
KLEINER PERKINS CAUFIELD & BYERS XI-A LP 10% Owner
X
KRAUSZ STEVEN M 10% Owner
FEDERMAN IRWIN 10% Owner
U S Venture Partners IX L P 10% Owner
LIDDLE DAVID E 10% Owner
Matteucci Paul A 10% Owner
ROOT JONATHAN D 10% Owner
YOUNG PHILIP M 10% Owner
Presidio Management Group IX, L.L.C. 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-06 4 Mead Dana G Jr. P D 26.2247 3,811 13,567 355,791
2018-08-15 4 Earnhardt Lisa D S X D 26.5097 -20,000 465,865 12,349,941
2018-08-15 4 Earnhardt Lisa D M D 13.05 5,000 485,865
2018-07-16 4 Earnhardt Lisa D S X D 33.0843 -20,000 480,865 15,909,082
2018-07-16 4 Earnhardt Lisa D M D 13.05 5,000 500,865
2018-07-10 4 Kaufman Richard E S X D 35.018 -7,000 87,512 3,064,495
2018-07-10 4 Kaufman Richard E M D 13.05 7,000 94,512
2018-06-15 4 Earnhardt Lisa D S X D 36.7855 -20,000 495,865 18,240,642
2018-06-15 4 Earnhardt Lisa D M D 13.05 5,000 515,865
2018-06-05 4 Mead Dana G Jr. A D 1,514 9,756
2018-06-05 4 VERNON W ANTHONY A D 1,514 4,060
2018-06-05 4 Kline Teresa L. A D 1,514 1,514
2018-06-05 4 MOLL FREDERIC H A D 1,514 241,138
2018-06-05 4 Lucchese Cynthia L A D 1,514 9,060
2018-06-05 4 GALLAHUE KIERAN A D 1,514 12,060
2018-06-05 4 HILLEMAN JERYL L S X D 41.7007 -12,833 23,432 977,131
2018-06-05 4 HILLEMAN JERYL L M D 11.12 12,833 36,265
2018-05-15 4 Earnhardt Lisa D S X D 39.2163 -15,000 510,865 20,034,235
2018-05-15 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-05-03 4 HILLEMAN JERYL L S X D 39.9414 -12,833 23,432 935,907
2018-05-03 4 HILLEMAN JERYL L M D 11.12 12,833 36,265
2018-04-16 4 Earnhardt Lisa D S X D 39.5945 -15,000 510,865 20,227,444
2018-04-16 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-04-03 4 HILLEMAN JERYL L S X D 37.6566 -12,833 23,432 882,369
2018-04-03 4 HILLEMAN JERYL L M D 11.12 12,833 36,265
2018-03-15 4 Earnhardt Lisa D S X D 38.3194 -15,000 510,865 19,576,040
2018-03-15 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-03-06 4 HILLEMAN JERYL L S X D 35.9207 -12,833 23,432 841,694
2018-03-06 4 HILLEMAN JERYL L M D 11.12 12,833 36,265
2018-02-15 4 Earnhardt Lisa D S X D 36.3959 -15,000 510,865 18,593,391
2018-02-15 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-02-06 4 HILLEMAN JERYL L S X D 35.7979 -12,833 12,932 462,938
2018-02-06 4 HILLEMAN JERYL L M D 11.12 12,833 25,765
2018-02-01 4 Kaufman Richard E S X D 37.2106 -958 87,512 3,256,374
2018-01-17 4 Parker Drake R. A D 3,000 3,000
2018-01-17 4 CARSCADDEN GWEN R. A D 5,300 9,156
2018-01-17 4 Kaufman Richard E A D 6,000 88,470
2018-01-17 4 Lehman David Aaron A D 7,500 15,213
2018-01-17 4 HILLEMAN JERYL L A D 10,500 23,432
2018-01-18 4 Earnhardt Lisa D S X D 33.4672 -11,166 510,865 17,097,221
2018-01-17 4 Earnhardt Lisa D A D 25,500 522,031
2018-01-17 4 Kaufman Richard E S X D 32.9796 -25,000 82,470 2,719,828
2018-01-16 4 Kaufman Richard E S X D 33.6865 -25,000 107,470 3,620,288
2018-01-12 4 CARSCADDEN GWEN R. S X D 34.3476 -10,000 3,856 132,444
2018-01-12 4 CARSCADDEN GWEN R. M D 12.19 10,000 13,856
2018-01-11 4 HILLEMAN JERYL L S X D 33.8052 -12,835 12,932 437,169
2018-01-11 4 HILLEMAN JERYL L M D 11.12 12,835 25,767
2018-01-01 4 CARSCADDEN GWEN R. F D 33.9328 -644 3,856
2018-01-01 4 Earnhardt Lisa D F D 33.9328 -6,834 496,531
2018-01-01 4 HILLEMAN JERYL L F D 33.9328 -2,068 12,932
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Moving Average Crossover Alert: Intersect ENT (XENT)

2018-08-14 zacks
Intersect ENT, Inc. (XENT - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for XENT broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

Intersect ENT (XENT) Reports Q2 Loss, Misses Revenue Estimates

2018-08-01 zacks
Intersect ENT (XENT - Free Report) just came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.

Intersect ENT's (XENT) CEO Lisa Earnhardt on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good afternoon, and welcome to the Intersect ENT First Quarter 2018 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. (4-0)

Large Opportunities And High Expectations Battling It Out At Intersect ENT

2018-03-28 seekingalpha
Intersect ENT's products have been shown to reduce inflammation, scarring, and the need for repeat procedures, but not all clinicians are sold on the cost-benefit trade-off. (45-0)